Formononetin-derived quantum dots suppress colon cancer growth by triggering mitochondrial apoptosis

Formononetin (FMN) is an extracted component of traditional Chinese medicine with anticancer effects, but its poor water solubility and low bioavailability have limited further research and application. Therefore, based on FMN that is the natural antitumor agent, we synthesized a formononetin quantum dots (FMNQDs) for colon cancer therapy, which has the advantages of outstanding water solubility, homogeneous particle size (2.03 ± 1.0 nm), exceptional stability and good intracellular fluorescence imaging effect. The results show that FMNQD exhibits good antitumor activity by inducing mitochondrial-mediated apoptosis, characterized by elevated intracellular reactive oxygen species (ROS) levels, decreased mitochondrial membrane potential (MMP), and modulated expression of Bax and Bcl-2. In <i>vivo</i> validation confirmed FMNQD's significant tumor growth inhibition. The tumor inhibition rate in the 8 mg/kg dose group was as high as 60.06 ± 6.22%. Moreover, blood biochemical analysis suggested a favorable safety profile. This study establishes FMNQDs as a potential therapeutic agent for colon cancer, providing preclinical evidence to support further development of formononetin-based nanomedicines.

Authors

Institutions

Publication Details

Journal
Nanomedicine
Published
2026-01-12
DOI
https://doi.org/10.1080/17435889.2026.2615097
Primary Topic
Carbon and Quantum Dots Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Formononetin-derived quantum dots suppress colon cancer growth by triggering mitochondrial apoptosis

Hongliang Bian, Min Xu, Tongjin Yin, Yuqing Cui et al.
Nanomedicine
Carbon and Quantum Dots Applications
article

Formononetin-derived quantum dots suppress colon cancer growth by triggering mitochondrial apoptosis

Hongliang Bian, Min Xu, Tongjin Yin, Yuqing Cui, Junfeng Zhang, Chenchen Li
article en

Abstract

Formononetin (FMN) is an extracted component of traditional Chinese medicine with anticancer effects, but its poor water solubility and low bioavailability have limited further research and application. Therefore, based on FMN that is the natural antitumor agent, we synthesized a formononetin quantum dots (FMNQDs) for colon cancer therapy, which has the advantages of outstanding water solubility, homogeneous particle size (2.03 ± 1.0 nm), exceptional stability and good intracellular fluorescence imaging effect. The results show that FMNQD exhibits good antitumor activity by inducing mitochondrial-mediated apoptosis, characterized by elevated intracellular reactive oxygen species (ROS) levels, decreased mitochondrial membrane potential (MMP), and modulated expression of Bax and Bcl-2. In <i>vivo</i> validation confirmed FMNQD's significant tumor growth inhibition. The tumor inhibition rate in the 8 mg/kg dose group was as high as 60.06 ± 6.22%. Moreover, blood biochemical analysis suggested a favorable safety profile. This study establishes FMNQDs as a potential therapeutic agent for colon cancer, providing preclinical evidence to support further development of formononetin-based nanomedicines.

NanomedicineVol. 21(4)
Anhui University of Science and Technology (CN), Nantong University (CN), Affiliated Hospital of Nantong University (CN), Hainan Medical University (CN)
Openalex Percentile: Top 90%
Carbon and Quantum Dots Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Formononetin-derived quantum dots suppress colon cancer growth by triggering mitochondrial apoptosis — Hongliang Bian, Min Xu, et al. · Nanomedicine (2026) | TGRS Research Map | TGRS